Inside the research

Intuitive Surgical, Inc.

ISRG Research profile · latest available data

Price overview

$405.18

▲ +5.66 (+1.4%)

52w hi$592.85
52w lo$332.02
Vol2.50M
As of25 Sep 2026

The Verdict

Hold

Our score -0.25

Short-0.49
Medium-0.18
Long+0.09

computed 2026-09-27

Key fundamentals

Intuitive Surgical, Inc.

Healthcare · Medical Instruments & Supplies

Market cap$145.17B
Enterprise value$138.05B
Trailing P/E46.52x
Forward P/E33.51x
EV / EBITDA33.02x
P / S (ttm)13.16x
Profit margin28.4%
Return on equity17.4%
Revenue growth+18.5%
Earnings growth+26.5%

Layer Breakdown

LayerRawContribution
Fundamental+0.24
Sector+0.08
Technical-0.38
Earnings+0.00
Sentiment+0.05

macro × 1.00 · 2026-09-27

Business overview

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.

United States · www.intuitive.com

Risk Metrics

Beta vs SPX1.18
Corr SPX0.54
Annual vol35.2%
Annual ret-3.0%
Sharpe-0.08
Max DD-45.6%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$577.01
High / Low$750.00 / $378.00
Median$580.00
Analysts30
Strong Buy7
Buy16
Hold9
Sell1
Strong Sell1

Recent rating actions

2026-04-23Barclays→ Overweight
2026-04-22Piper Sandler→ Overweight
2026-04-22Leerink Partners→ Outperform
2026-04-22BTIG→ Buy
2026-04-22Baird→ Outperform
2026-04-15Truist Securities→ Buy

Material Events

DateEvent8-K
2026-07-27Bylaws Amendment, Exhibitsread
2026-07-16Earnings Release, Exhibitsread
2026-05-28Officer / Director Change, Exhibitsread
2026-05-04Officer / Director Change, Shareholder Vote…read
2026-04-21Earnings Release, Exhibitsread
2026-03-02Other Material Event, Exhibitsread
2026-01-22Earnings Release, Exhibitsread
2026-01-14Earnings Release, Exhibitsread
2025-12-18Officer / Director Changeread
2025-10-21Earnings Release, Exhibitsread
2025-07-22Earnings Release, Exhibitsread
2025-05-15Officer / Director Change, Reg FD Disclosure…read

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-11GUTHART GARY SSell10.00K$4.00M
2026-08-11Ladd Amy LSell72$28.30K
2026-08-10LOEB GARYEVP & Chief Legal and ComSell400$151.60K
2026-08-10Ladd Amy LSell400$151.60K
2026-07-31Brosius MarkEVP & Chief Mfg and SupplSell28$9.83K
2026-07-30Brosius MarkEVP & Chief Mfg and SupplSell28$9.71K
2026-07-29Brosius MarkEVP & Chief Mfg and SupplSell28$10.09K
2026-07-28Brosius MarkEVP & Chief Mfg and SupplSell28$10.24K
2026-07-27Brosius MarkEVP & Chief Mfg and SupplSell28$9.63K
2026-07-10Rosa David J.Chief Executive Officer (Option exercise1.91K—

Flow & Concentration

Insider 180d net-$4.89M
Insider buys / sells0 / 17
Insider biasSellers
13F holders10
Top-5 share96.4%
HHI4,245 (concentrated)

Top Holders

HolderValueShares
State Street Corp$6.39B16.06M
Fidelity / FMR LLC$1.69B4.25M
Citadel Advisors$863.95M2.17M
Capital Research / Capital World$764.08M1.92M
Millennium Management$226.18M568.74K
Renaissance Technologies$200.60M504.43K
AQR Capital Management$133.93M336.78K
Ark Invest$27.99M70.38K
Bridgewater Associates$7.68M19.32K
T. Rowe Price Group$4.48M11.26M

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-124view
2026-08-114view
2026-08-104view
2026-07-314view
2026-07-294view
2026-07-278-Kview
2026-07-2110-Qview
2026-07-168-Kview
2026-07-134view
2026-06-124view
2026-06-104view
2026-06-104view
2026-06-104view
2026-06-024view
2026-05-288-Kview

The Long Run

FY 2009–2025 · 17 years

LineLatestCAGRTrend
Revenue$10.06B+19.3%
Gross profit$6.64B+14.6%
Operating income$2.95B+18.1%
Net income$2.86B+17.0%
Cash from ops$3.03B+13.8%

Indices

NASDAQ-100S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$397.65$406.39$391.92$405.182.50M
Sep 24$396.73$404.19$395.18$399.521.56M
Sep 23$400.88$404.44$396.05$398.301.69M
Sep 22$403.00$403.97$397.72$402.091.86M
Sep 21$393.89$403.48$391.04$401.652.97M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →